Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company dedicated to the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company's core mission is to treat serious diseases by modulating the effects of the hormone cortisol, addressing conditions with high unmet medical needs. Headquartered in Redwood City, California, Corcept focuses on pioneering treatments within the field of cortisol modulation.

Corcept's product portfolio includes Korlym (mifepristone), the first FDA-approved oral medication for controlling hyperglycemia secondary to hypercortisolism (Cushing's syndrome) in adult patients. Expanding its therapeutic reach, the company recently received FDA approval in March 2026 for Lifyorli (relacorilant) for the treatment of patients with platinum-resistant ovarian cancer. Corcept also maintains a robust pipeline of selective cortisol modulators, with candidates like dazucorilant in clinical trials for Amyotrophic Lateral Sclerosis (ALS) and miricorilant for metabolic dysfunction-associated steatohepatitis (MASH).

Recent notable developments include the FDA approval of Lifyorli, marking a significant step in the company's oncology program. Furthermore, positive two-year overall survival data from the Phase 2 DAZALS study for dazucorilant in ALS patients has been reported, with a Phase 3 trial anticipated to commence later in 2026. Despite a recent Complete Response Letter from the FDA regarding relacorilant for Cushing's syndrome, Corcept remains engaged with regulators for its approval. Led by CEO Joseph K. Belanoff, MD, Corcept has increased its 2026 revenue guidance to $950 – $1,050 million and expects to return to profitability in the second quarter of 2026, signaling its transition from a single-product entity to a multi-product player in rare diseases and oncology.